在败血症休克中使用皮质类固醇:双刃剑.
1Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Current opinion in critical care
|June 30, 2025
概括
对于败血症休克的皮质类固醇治疗有争议. 虽然指导方针建议使用它,特别是在耐火病例中,但由于不确定的益处和潜在危害,个性化治疗至关重要.
科学领域:
- 临界护理医学 临界护理医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在性休克中使用皮质类固醇治疗是有争议的.
- 葡萄糖皮质类药物提供潜在的免疫调节益处,可以解决下丘脑-垂体-上腺 (HPA) 轴调节障碍.
- 临床试验结果相互矛盾,导致治疗指南的不确定性,并引起对不良影响的担忧.
研究的目的:
- 审查和解释当前关于在败血症休克中使用皮质类固醇的证据.
- 探索葡萄糖皮质类药物在治疗败血症休克中的作用.
- 为了确定未来的研究方向,在这种情况下进行皮质类固醇治疗.
主要方法:
- 系统审查和解释现有临床证据.
- 分析来自临床试验和系统审查的数据.
- 评估当前的指导方针和处方做法.
主要成果:
- 目前的指导方针建议在败血症休克时使用皮质类固醇.
- 社区获得性肺炎 (CAP) 和急性呼吸困难综合征 (ARDS) 的新兴数据可能会影响败血症休克的结果.
- 结合治疗与弗鲁德科尔提松显示了潜在的益处,需要进一步调查.
- 在临床医生和重症监护室 (ICU) 之间,皮质类固醇处方模式存在显著的变化.
结论:
- 皮质类固醇在败血症休克中的有用性仍然不确定.
- 皮质类固醇在选择的患者中对耐火性休克有价值,当益处超过风险时.
- 未来的研究应该优先考虑在败血症休克时给予皮质类固醇的个性化方法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
399
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
399
COPD: Management Using Bronchodilators and Corticosteroids
324
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
324
Pericarditis III: Medical Management
30
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
30
Heart Failure Drugs: Inotropic Agents
743
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
743
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277


